Cargando…

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain

BACKGROUND AND OBJECTIVES: To examine the efficacy of ubrogepant in the treatment of migraine with mild vs moderate or severe pain. METHODS: This was a phase 3, open-label, dose-blinded, 52-week extension trial. Adults with migraine were randomized 1:1:1 (usual care, ubrogepant 50 mg, or ubrogepant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lipton, Richard B., Dodick, David W., Goadsby, Peter J., Burstein, Rami, Adams, Aubrey M., Lai, Jeff, Yu, Sung Yun, Finnegan, Michelle, Kuang, Amy W., Trugman, Joel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620813/ https://www.ncbi.nlm.nih.gov/pubmed/35977836 http://dx.doi.org/10.1212/WNL.0000000000201031

Ejemplares similares

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020)

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
por: Hutchinson, Susan, et al.
Publicado: (2021)

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II
por: Dodick, David W., et al.
Publicado: (2020)

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
por: Goadsby, Peter J, et al.
Publicado: (2019)

Ubrogepant to Treat Acute Migraine in Adults
por: Edinoff, Amber N., et al.
Publicado: (2021)

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
por: Manack Adams, Aubrey, et al.
Publicado: (2023)

Ubrogepant in the Acute Management of Migraine: A Narrative Review
por: Chiang, Chia-Chun, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Mechanistic Investigations Support Liver Safety of Ubrogepant
por: Smith, Brenda, et al.
Publicado: (2020)

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
por: Lipton, Richard B., et al.
Publicado: (2022)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
por: Navratilova, Edita, et al.
Publicado: (2020)

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
por: Jakate, Abhijeet, et al.
Publicado: (2020)

Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine
por: Dighriri, Ibrahim M, et al.
Publicado: (2023)

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Comorbid pain and migraine chronicity: The Chronic Migraine Epidemiology and Outcomes Study
por: Scher, Ann I., et al.
Publicado: (2017)

Correction to: Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
por: Dodick, David W., et al.
Publicado: (2016)

Migraine headache is present in the aura phase – a prospective study
por: Hansen, JM, et al.
Publicado: (2013)

Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis
por: Zhang, Zizhen, et al.
Publicado: (2021)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine
por: Stovner, Lars Jacob, et al.
Publicado: (2022)

Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO Study
por: Lipton, Richard B., et al.
Publicado: (2019)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study
por: Buse, Dawn C., et al.
Publicado: (2020)

Systematic review of outcomes and endpoints in preventive migraine clinical trials
por: McGinley, James S., et al.
Publicado: (2021)

Systematic review of outcomes and endpoints in acute migraine clinical trials
por: Houts, Carrie R., et al.
Publicado: (2021)

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
por: Saper, Joel R, et al.
Publicado: (2011)

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
por: Jakate, Abhijeet, et al.
Publicado: (2021)

Treatment preferences and the selection of acute migraine medications: results from a population-based survey
por: Lipton, Richard B., et al.
Publicado: (2004)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains
por: Burstein, Rami, et al.
Publicado: (2014)

Mild traumatic brain injury affects the features of migraine
por: Ishii, Ryotaro, et al.
Publicado: (2021)

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Trial
por: Yarnitsky, David, et al.
Publicado: (2019)

Migraine in the Young Brain: Adolescents vs. Young Adults
por: Colon, Elisabeth, et al.
Publicado: (2019)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
por: Schwedt, Todd J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7f9h3cgg9s97rsmq4r3n4donqq